Status:
UNKNOWN
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Lead Sponsor:
Ospedale Maggiore Di Trieste
Conditions:
Acute Myeloid Leukemia, Adult
Hypomethylating Agents
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid...
Detailed Description
The prognosis of acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy is poor (Kantarjian et al). Hypomethylating agents, azacitidine and decitabine, are effective and l...
Eligibility Criteria
Inclusion
- age ≥18 years
- newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy
Exclusion
- promyelocytic acute myeloid leukemia
- patients who have already received one or more prior lines of therapy
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04454580
Start Date
August 1 2020
End Date
September 30 2020
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SC Ematologia Ospedale Maggiore
Trieste, Italy, 34100